Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Ovid Therapeutics

06/08/2021 14:57

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected to show a
no change in quarterly revenue when it reports results on August
9 (estimated). 
​* Refinitiv's mean analyst estimate for Ovid Therapeutics Inc
is for a loss of 16 cents per share. For the same quarter last
year, the company reported a loss of 41 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Ovid
Therapeutics Inc is $4.25​, about 12% above​ its last closing
price of $3.74. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  1.39        1.68       2.53      Beat    50.8
 Dec. 31 2020  -0.25       -0.31      -0.34     Missed  -9.7
 Sep. 30 2020  -0.34       -0.36      -0.28     Beat    22.6​
 Jun. 30 2020  -0.35       -0.36      -0.41     Missed  -15
 Mar.          -0.33​      -0.33      -0.37     Missed  -11.6​
 31​ 2020​                                              
 Dec. 31 2019  -0.37       -0.41      -0.35     Beat    14.4​
 Sep. 30 2019  -0.36       -0.36      -0.43     Missed  -18.3
 Jun. 30 2019  -0.43       -0.43      -0.34     Beat    21.3
 This summary was machine generated August 6 at 13:57 GMT.  All
figures in US dollars unless otherwise stated